{"id":5946,"date":"2025-03-16T15:30:31","date_gmt":"2025-03-16T12:30:31","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=5946"},"modified":"2025-03-16T15:30:31","modified_gmt":"2025-03-16T12:30:31","slug":"tavr-in-africa-high-success-rate-but-above-average-risks","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/tavr-in-africa-high-success-rate-but-above-average-risks\/","title":{"rendered":"TAVR in Africa: High Success Rate but Above-Average Risks"},"content":{"rendered":"
TAVR in Africa: High Success Rate but Above-Average Risks<\/div>\n
<\/div>\n
Source: International journal of CARDIOLOGY| March 10, 2025 | \u00a0| TAVR<\/div>\n
<\/div>\n
1. <\/span>TAVR Adoption and New Findings<\/div>\n
<\/span>\u2022 <\/span>Transcatheter aortic valve replacement (TAVR) adoption in Africa has been slower than in other regions.<\/div>\n
<\/span>\u2022 <\/span>A new study published in the International Journal of Cardiology found that while procedural success rates are high, mortality and complication risks remain above average.<\/div>\n
<\/span>2. <\/span>Updated Guidelines and Need for Local Data<\/div>\n
<\/span>\u2022 <\/span>The South African Society of Cardiovascular Intervention and the Society of Cardiothoracic Surgeons of South Africa have updated their TAVR guidelines, stressing the importance of expanding access and analyzing local patient outcomes.<\/div>\n
<\/span>\u2022 <\/span>Evaluating TAVR results in diverse populations and healthcare systems is critical for improving patient selection and treatment strategies.<\/div>\n
<\/span>3. <\/span>Study Overview<\/div>\n
<\/span>\u2022 <\/span>A meta-analysis of seven observational studies (published through August 2024) examined 704 TAVR patients from South Africa, Egypt, Tunisia, and Algeria.<\/div>\n
<\/span>\u2022 <\/span>Patient demographics:<\/div>\n
<\/span>\u2022 <\/span>Average age: 79 years<\/div>\n
<\/span>\u2022 <\/span>Gender: 52% male<\/div>\n
<\/span>\u2022 <\/span>Mean Logistic EuroScore: 25.57% (indicating a high-risk population)<\/div>\n
<\/span>4. <\/span>Key Outcomes<\/div>\n
<\/span>\u2022 <\/span>Procedural success rate: 91%<\/div>\n
<\/span>\u2022 <\/span>Average hospital stay: 5.2 days<\/div>\n
<\/span>\u2022 <\/span>In-hospital complications:<\/div>\n
<\/span>\u2022 <\/span>Mortality: 5%<\/div>\n
<\/span>\u2022 <\/span>Stroke\/Transient Ischemic Attack (TIA): 2%<\/div>\n
<\/span>\u2022 <\/span>Major bleeding: 8%<\/div>\n
<\/span>\u2022 <\/span>Permanent pacemaker (PPM) implantation: 7%<\/div>\n
<\/span>\u2022 <\/span>One-year outcomes:<\/div>\n
<\/span>\u2022 <\/span>Mortality rate: 11%<\/div>\n
<\/span>\u2022 <\/span>Stroke\/TIA rate: 6%<\/div>\n
<\/span>5. <\/span>Comparison with International Data<\/div>\n
<\/span>\u2022 <\/span>While TAVR success rates in Africa are comparable to global standards, complication rates (mortality, stroke, and bleeding) are higher than in the U.S. and Germany.<\/div>\n
<\/span>\u2022 <\/span>The findings suggest disparities in cardiovascular care that need further investigation.<\/div>\n
<\/span>6. <\/span>Call for More Research and Global Equity<\/div>\n
<\/span>\u2022 <\/span>The study highlights the importance of continued research on TAVR outcomes in Africa and other regions with slow adoption.<\/div>\n
<\/span>\u2022 <\/span>Addressing these disparities is essential for improving cardiovascular care globally.<\/div>\n
<\/div>\n
This research underscores the need for improved infrastructure, training, and post-procedural care to ensure that TAVR benefits all patients equally worldwide.<\/div>\n
https:\/\/www.internationaljournalofcardiology.com\/article\/S0167-5273(25)00182-2\/fulltext<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

TAVR in Africa: High Success Rate but Above-Average Risks Source: International journal of CARDIOLOGY| March 10, 2025 | \u00a0| TAVR 1. TAVR Adoption and New Findings \u2022 Transcatheter aortic valve replacement (TAVR) adoption in Africa has been slower than in other regions. \u2022 A new study published in the International Journal of Cardiology found that […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5946","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=5946"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5946\/revisions"}],"predecessor-version":[{"id":5947,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5946\/revisions\/5947"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=5946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=5946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=5946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}